BTK and B-cell chronic lymphocytic leukemia: As the BTK inhibitor ibrutinib has been approved for mantle cell lymphoma and chronic lymphocytic leukemia, and has been shown to be well tolerated by patients with few adverse effects, we thought that ibrutinib could also be effective against inflammasome-dependent diseases including ischaemic stroke.